Anavex Life Sciences Corp (AVXL) - Total Liabilities
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) has total liabilities worth $7.69 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Anavex Life Sciences Corp's assets to evaluate the company's liquid asset resilience ratio.
Anavex Life Sciences Corp - Total Liabilities Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Anavex Life Sciences Corp total assets.
Anavex Life Sciences Corp Competitors by Total Liabilities
The table below lists competitors of Anavex Life Sciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Netronix
TWO:6143
|
Taiwan | NT$3.59 Billion |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
Israel | ILA404.39 Million |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
USA | $20.04 Million |
|
Taisun Enterprise Co Ltd
TW:1218
|
Taiwan | NT$2.44 Billion |
|
APRANGA AB EO 029
F:WHX
|
Germany | €96.84 Million |
|
KABE Group AB (publ.)
ST:KABE-B
|
Sweden | Skr1.00 Billion |
|
Sovereign Metals Ltd
AU:SVM
|
Australia | AU$4.46 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Anavex Life Sciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Anavex Life Sciences Corp balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anavex Life Sciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual total liabilities of Anavex Life Sciences Corp from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $8.95 Million | -41.54% |
| 2024-09-30 | $15.30 Million | +22.10% |
| 2023-09-30 | $12.53 Million | +22.71% |
| 2022-09-30 | $10.21 Million | -5.41% |
| 2021-09-30 | $10.80 Million | +47.81% |
| 2020-09-30 | $7.31 Million | +44.96% |
| 2019-09-30 | $5.04 Million | +29.73% |
| 2018-09-30 | $3.88 Million | +8.38% |
| 2017-09-30 | $3.58 Million | +12.34% |
| 2016-09-30 | $3.19 Million | +19.90% |
| 2015-09-30 | $2.66 Million | -62.84% |
| 2014-09-30 | $7.16 Million | +150.67% |
| 2013-09-30 | $2.86 Million | -1.10% |
| 2012-09-30 | $2.89 Million | +114.67% |
| 2011-09-30 | $1.35 Million | -59.11% |
| 2010-09-30 | $3.29 Million | -22.89% |
| 2009-09-30 | $4.27 Million | +85.55% |
| 2008-09-30 | $2.30 Million | +397.13% |
| 2007-09-30 | $462.53K | +1551.54% |
| 2006-09-30 | $28.01K | +3.74% |
| 2005-09-30 | $27.00K | +977.72% |
| 2004-09-30 | $2.50K | -- |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more